A prospective study was done on patients, attending endocrine OPD in Institute of Medicine, Kathmandu, Nepal, with diagnosis of thyrotoxicosis at their first visit and in whom Thyroid technetium scan could be done. Confirmed diagnosis of thyrotoxicosis was made on clinical grounds along with values of Thyroid Stimulating Hormone (TSH) less than 0.1µ IU/ml [5]. The study was conducted from mid-June 2016 to February 2017 and total 55 patients were taken. Patients taking drugs that affect TFT or those who have already started antithyroid medication, patients below 15 years of age, pregnancy, patients with painful thyroiditis or palpable nodules, patients with obvious features of graves’ disease and single or multiple nodules discovered in thyroid scintigraphy were excluded. TFT reports of patient at their first visit were recorded. Ethical clearance to conduct the study was taken from the Institutional Research Board. Informed consent was taken from patient to be part of this study. Assay of TFT was performed on Enhanced Chemiluminescence Immunoassay (ECI) on VitrosDiagnostic, Johnsons and Johnsons; in Central Biochemistry Laboratory of Institute of Medicine (IOM), Maharajgunj. Technetium 99m Thyroid Scan was done at Gamma Imaging centre in Maharajgunj, Kathmandu. Intravenous administration of 5 mCi dosage of Tc 99m- per technetate was done and static image of thyroid gland after 20 minutes in multiple projection was taken. Quantification of total uptake of tracer by the gland was taken as percentage uptake of right and left lobe thus giving total uptake. Normal reference of total percentage uptake range was 0.5%-4%. Uptake values below 0.5% was diagnosed as DIT and above 4% as GD.

Statistical analysis was performed using SPSS software version 20.0. Ratio of free T₃ and free T₄ both in pmol/L was obtained in each case. Data are presented as mean±SD (standard deviation). Receiver Operating Characteristic (ROC) curve was prepared to obtain cut off value for discriminating GD from DIT along with sensitivity and specificity.

Out of 55 patients 43 (78.18%) were females and 12 (21.81%) were males. Mean age of patient was 43.8±15.7 (range 16-67 years). Of these patients 23 (41.81%) were diagnosed with GD and 32 (58.18%) were diagnosed with DIT using Technetium 99m Thyroid Scan.

Mean ratio of fT₃ to fT₄ in GD was 0.395 with standard deviation 0.085 (95% CI: 0.358 to 0.432) and mean ratio of fT₃ to fT₄ in DIT was 0.287 with standard deviation 0.059 (95% CI: 0.265 to 0.309) as shown in [Table/Fig-1]. On Receiver Operating Characteristic (ROC) curve analysis [Table/Fig-2] cut off ratio was 0.3050 with sensitivity of 87% and specificity of 62.5%.

[Table/Fig-2]:

ROC curve.

Prevalence of thyrotoxicosis in central region of Nepal is 3% [1]. Clinical differentiation between cases of GD and DIT is possible when signs of Graves’ disease are present like eye signs. Most of the times these two entities cannot be differentiated clinically. Various laboratory parameters have been advocated for differentiation like testing for TSH Receptor Antibody (TRAb) [6], use of nuclear medicine [3], peripheral eosinophil/monocyte ratio [3] and serial changes in liver function test [7]. None of these tests are suitable due to unavailability or difficulty in use and identification of simple measure for differentiation like, ratio of fT3 to fT4 is useful in our context. Our result is consistent with the findings of previous literature [3].

These types of studies conducted previously were mostly retro-spective in design based on medical records [4]. One of the way our prospective design is superior is that we could purposively choose cases where frank signs of Graves’ disease or nodules were absent on clinical examination leading to diagnostic dilemma between GD and DIT. Sometimes during recovery phase of thyroiditis, the radioactive iodine uptake increases and scan demonstrates increased activity leading to confusion with Graves’ disease [8]. So, these group of patients were excluded from our study by asking their clinical history of interval decline in symptoms. Radionuclide thyroid scanning using technetium pertechnetate (Tc99m) is useful in differential diagnosis of GD and DIT and identifies other benign thyroidal illness like thyroid nodules [9]. Thyroid uptake of Tc99m and then imaging is the principal nuclear test in thyroid scan [5]. Very low thyroid uptake suggests destructive event leading to thyroiditis and increased uptake is seen in Graves’ disease [10]. All cases were scanned at same place, Gamma Imaging Centre at Maharajgunj to avoid discrepancies in result. Normal reference of total percentage uptake range was taken as 0.5%-4%. Uptake value less than 0.5% was diagnosed as destructive thyroiditis since radio uptake of tracer decreases due to destruction of cells. Values more than 4% uptake were taken as GD as activity throughout the gland is increased. Sometimes in recovery phase of DIT, the radio uptake may increase giving the values in between 0.5%-4%. So, these groups of patients were also excluded from the study.

Serum free T3, T4 and TSH were measured by fully automated Enhanced Chemiluminiscent Immunoanalyzer (Ortho Diagnostic;Johnson and Johnson Company). The assay validity was confirmed by concomitant quality control runs. Thyroid scan can be omitted and a diagnosis of DIT can be made if serum free T₃ to free T₄ ratio is below 0.30 in thyrotoxicosis patients. The ratio above 0.30 likely confirms diagnosis of GD. T₃ is active form of thyroid hormone that is deiodinated from T₄ by iodothyronine deiodinase [11]. High expression of this deiodinase in Graves thyroid tissue contributes to higher serum T₃ level [12]. This provides the meaningful explanation for the basis of variable fT₃ and fT₄ ratio among patients with two different aetiologies with similar presentation. Since patient of Graves’ disease might need radio ablative therapy after a mean time, so thyroid scanning can be recommended depending on patient’s clinical status. But thyroid scan can be avoided if fT₃ to fT₄ ratio is below 0.30. No supporting data regarding usefulness of serum fT₃ to fT₄ ratio in differentiation of GD and DIT previously exist in Nepalese population. The finding of this study is very helpful for the patients and clinician in our setting where patient’s compliance is poor and resources are limited.

Selection of patients from single centre is the limitation of this study. Another limitation is small sample size that represents only central region of Nepal.

If free T₃ to free T₄ ratio is below 0.30 the diagnosis of DIT can be made and this tool obviates unnecessary expensive and easily inaccessible thyroid scan.